Suratadenoturev is under clinical development by Oncolys BioPharma and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction. According to GlobalData, Phase II drugs for Adenocarcinoma Of The Gastroesophageal Junction have a 51% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Suratadenoturev’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Suratadenoturev overview
Suratadenoturev (OBP-301) is under development for the treatment of gastric cancer, gastroesophageal junction adenocarcinoma, hepatocellular carcinoma, esophageal squamous cell cancer, esophageal adenocarcinoma, metastatic melanoma, non small cell lung cancer, neuroblastoma and hepatocellular carcinoma. The drug candidate is administered by intratumoral route. It is a therapeutic modality derived from adenovirus. Telomelysin is generated by replacing the normal transcriptional regulatory element of the E1A gene in the human adenovirus type 5 with the human telomerase reverse transcriptase (hTERT) promoter (oncolytic type 5 adenovirus). The drug candidate is developed based on oncolytic adenovirus technology. It was also under development for the treatment of sarcoma, head and neck squamous cell cancer, oropharyngeal cancer, hypopharyngeal cancer, laryngeal cancer, oral cavity (mouth) cancer, head and neck cancer squamous cell carcinoma. The drug candidate is an new molecular entity (NME).
Oncolys BioPharma overview
Oncolys BioPharma (Oncolys) is a biotechnology company that discovers and develops drugs for the treatment of cancer and infectious diseases. The company’s pipeline product includes OBP-301, OBP-601, OBP-2011, OBP 801 and OBP-702. Its other pipeline includes OBP-401 and OBP-1101. The company’s pipeline indications include esophageal cancer, gastric cancer, hepatocellular carcinoma, C9-ALS/FTD, progressive supranuclear palsy, atypical glandular cells, COVID-19, solid tumor and ophthalmic use, among others. It also provides consulting services for the development of biotechnology drugs. The company operates in Japan and the US. Oncolys is headquartered in Minato-Ku, Tokyo, Japan
For a complete picture of Suratadenoturev’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
